Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

British Journal of Cancer (10)
Oncogene (2)
Nature Cancer (2)
Leukemia (1)
Cell Death and Differentiation (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (14)
Amendments and Corrections (1)
Reviews (1)

Subject Check one or more subjects to show results from those subjects only.

Biomarkers
Cancer
Diseases
Health care
Medical research

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–16 of 16 results

Advanced filters: Author: S Ugurel Clear advanced filters

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2

D Bedognetti
T L Spivey
F M Marincola
ResearchOpen Access15 Oct 2013
British Journal of Cancer

Volume: 109, P: 2412-2423
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

M S Carlino
L E Haydu
G V Long
ResearchOpen Access10 Jun 2014
British Journal of Cancer

Volume: 111, P: 292-299
Lack of clinical efficacy of imatinib in metastatic melanoma

S Ugurel
R Hildenbrand
D Schadendorf
ResearchOpen Access20 Apr 2005
British Journal of Cancer

Volume: 92, P: 1398-1405
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

Roesch and colleagues use clinical datasets and mouse models of BRAF-mutant melanoma to reveal a role for IL-17A in positive responses to anti-PD-1 and anti-CTLA-4 therapy, which they also link to infiltrating neutrophils.

Renáta Váraljai
Lisa Zimmer
Alexander Roesch
ResearchOpen Access31 Jul 2023
Nature Cancer

Volume: 4, P: 1292-1308
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma

Renáta Váraljai
Lisa Zimmer
Alexander Roesch
Amendments and CorrectionsOpen Access14 Aug 2023
Nature Cancer

Volume: 4, P: 1395
Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

A Hauschild
C Garbe
W Tilgen
ResearchOpen Access17 Apr 2001
British Journal of Cancer

Volume: 84, P: 1036-1042
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial

A P Algazi
E Cha
A I Daud
ResearchOpen Access31 Mar 2015
British Journal of Cancer

Volume: 112, P: 1326-1331
Dose-dependent severe cutaneous reactions to imatinib

S Ugurel
R Hildenbrand
D Schadendorf
ResearchOpen Access15 Apr 2003
British Journal of Cancer

Volume: 88, P: 1157-1159
Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response

L P Rivory
K A Slaviero
S J Clarke
ResearchOpen Access23 Jul 2002
British Journal of Cancer

Volume: 87, P: 277-280
Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia

S Molica
G Vitelli
G Digiesi
Research25 Jan 2002
British Journal of Cancer

Volume: 86, P: 31-35
c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression

S S Ganguly
L S Fiore
R Plattner
Research05 Sept 2011
Oncogene

Volume: 31, P: 1804-1816
CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion

S Singh
K C Nannuru
R K Singh
ResearchOpen Access28 Apr 2009
British Journal of Cancer

Volume: 100, P: 1638-1646
Phase II trial of imatinib mesylate in patients with metastatic melanoma

K B Kim
O Eton
V G Prieto
ResearchOpen Access19 Aug 2008
British Journal of Cancer

Volume: 99, P: 734-740
CD4⁺CD7⁻ leukemic T cells from patients with Sézary syndrome are protected from galectin-1-triggered T cell death

G Rappl
H Abken
U Reinhold
Research02 May 2002
Leukemia

Volume: 16, P: 840-845
Apoptosis and melanoma chemoresistance

María S Soengas
Scott W Lowe
Reviews19 May 2003
Oncogene

Volume: 22, P: 3138-3151
The CD7⁻ subset of CD4⁺ memory T cells is prone to accelerated apoptosis that is prevented by interleukin-15 (IL-15)

G Rappl
H Abken
U Reinhold
Research01 May 2001
Cell Death & Differentiation

Volume: 8, P: 395-402